Safety of alisertib in the treatment of solid and hematological cancers: A systematic review and meta-analysis of randomized controlled trials

Zaher Mutaz Ashour, Aws Khalid Abushanab, Osama Wadah Rammaha, ab Theeb Mustafa, Ghayda Osama Alhaj, Aya Ahmad Al-Marahleh, Tasneem Aloqaili, Ahmad Sami Othman, Nour Maher Mustafa, Yihea Mohammad Al-Mashaqbah

Journal of Oncology Pharmacy Practice

Published online on August 26, 2025

Abstract

Journal of Oncology Pharmacy Practice, Ahead of Print.
BackgroundAlisertib, an Aurora kinase A inhibitor, has been investigated as a potential treatment for various hematologic and solid tumors. While clinical trials have suggested its efficacy in both cancer types, concerns persist regarding its safety ...